428 related articles for article (PubMed ID: 37020540)
1. Insights into the role of nucleotide methylation in metabolic-associated fatty liver disease.
Zhang N; Tian X; Yan T; Wang H; Zhang D; Lin C; Liu Q; Jiang S
Front Immunol; 2023; 14():1148722. PubMed ID: 37020540
[TBL] [Abstract][Full Text] [Related]
2. Neutrophil: An emerging player in the occurrence and progression of metabolic associated fatty liver disease.
Chen S; Guo H; Xie M; Zhou C; Zheng M
Int Immunopharmacol; 2021 Aug; 97():107609. PubMed ID: 33887577
[TBL] [Abstract][Full Text] [Related]
3. Metabolic dysfunction-associated fatty liver disease (MAFLD): an update of the recent advances in pharmacological treatment.
Sangro P; de la Torre Aláez M; Sangro B; D'Avola D
J Physiol Biochem; 2023 Nov; 79(4):869-879. PubMed ID: 36976456
[TBL] [Abstract][Full Text] [Related]
4. The role of protein kinases as key drivers of metabolic dysfunction-associated fatty liver disease progression: New insights and future directions.
Alshehade S; Alshawsh MA; Murugaiyah V; Asif M; Alshehade O; Almoustafa H; Al Zarzour RH
Life Sci; 2022 Sep; 305():120732. PubMed ID: 35760093
[TBL] [Abstract][Full Text] [Related]
5. Non-invasive screening, staging and management of metabolic dysfunction-associated fatty liver disease (MAFLD) in type 2 diabetes mellitus patients: what do we know so far ?
Binet Q; Loumaye A; Preumont V; Thissen JP; Hermans MP; Lanthier N
Acta Gastroenterol Belg; 2022; 85(2):346-357. PubMed ID: 35709779
[TBL] [Abstract][Full Text] [Related]
6. Toll-like receptors and metabolic (dysfunction)-associated fatty liver disease.
Khanmohammadi S; Kuchay MS
Pharmacol Res; 2022 Nov; 185():106507. PubMed ID: 36252773
[TBL] [Abstract][Full Text] [Related]
7. Progress in the Treatment of Metabolic-Related Fatty Liver Disease.
Zhang B; Feng Y; Lu J
Altern Ther Health Med; 2023 Oct; 29(7):86-93. PubMed ID: 37535913
[TBL] [Abstract][Full Text] [Related]
8. Nuclear factor erythroid 2-related factor 2-mediated signaling and metabolic associated fatty liver disease.
Bukke VN; Moola A; Serviddio G; Vendemiale G; Bellanti F
World J Gastroenterol; 2022 Dec; 28(48):6909-6921. PubMed ID: 36632321
[TBL] [Abstract][Full Text] [Related]
9. Current perspectives on the pathophysiology of metabolic associated fatty liver disease: are macrophages a viable target for therapy?
Kjær MB; George J; Kazankov K; Grønbæk H
Expert Rev Gastroenterol Hepatol; 2021 Jan; 15(1):51-64. PubMed ID: 32878486
[TBL] [Abstract][Full Text] [Related]
10. Circulating chemerin levels in metabolic-associated fatty liver disease: a systematic review and meta-analysis.
Ren Q; Wang H; Zeng Y; Fang X; Wang M; Li D; Huang W; Xu Y
Lipids Health Dis; 2022 Mar; 21(1):27. PubMed ID: 35236351
[TBL] [Abstract][Full Text] [Related]
11. Update on genetics and epigenetics in metabolic associated fatty liver disease.
Zhu X; Xia M; Gao X
Ther Adv Endocrinol Metab; 2022; 13():20420188221132138. PubMed ID: 36325500
[TBL] [Abstract][Full Text] [Related]
12. Infections at the nexus of metabolic-associated fatty liver disease.
Boeckmans J; Rombaut M; Demuyser T; Declerck B; Piérard D; Rogiers V; De Kock J; Waumans L; Magerman K; Cartuyvels R; Rummens JL; Rodrigues RM; Vanhaecke T
Arch Toxicol; 2021 Jul; 95(7):2235-2253. PubMed ID: 34027561
[TBL] [Abstract][Full Text] [Related]
13. Dietary Quality and Relationships with Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) among United States Adults, Results from NHANES 2017-2018.
Tian T; Zhang J; Xie W; Ni Y; Fang X; Liu M; Peng X; Wang J; Dai Y; Zhou Y
Nutrients; 2022 Oct; 14(21):. PubMed ID: 36364767
[TBL] [Abstract][Full Text] [Related]
14. Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B.
van Kleef LA; Choi HSJ; Brouwer WP; Hansen BE; Patel K; de Man RA; Janssen HLA; de Knegt RJ; Sonneveld MJ
JHEP Rep; 2021 Oct; 3(5):100350. PubMed ID: 34557660
[TBL] [Abstract][Full Text] [Related]
15. [Research progress of celastrol on the prevention and treatment of metabolic associated fatty liver disease].
Liu YC; Zhang Y; Qin SC; Xue JL
Sheng Li Xue Bao; 2023 Oct; 75(5):682-690. PubMed ID: 37909139
[TBL] [Abstract][Full Text] [Related]
16. Fibrogenic Pathways in Metabolic Dysfunction Associated Fatty Liver Disease (MAFLD).
Subramanian P; Hampe J; Tacke F; Chavakis T
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35805998
[TBL] [Abstract][Full Text] [Related]
17. Molecular Advances in MAFLD-A Link between Sphingolipids and Extracellular Matrix in Development and Progression to Fibrosis.
Kołakowski A; Dziemitko S; Chmielecka A; Żywno H; Bzdęga W; Charytoniuk T; Chabowski A; Konstantynowicz-Nowicka K
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232681
[TBL] [Abstract][Full Text] [Related]
18. MAFLD identifies patients with significant hepatic fibrosis better than NAFLD.
Yamamura S; Eslam M; Kawaguchi T; Tsutsumi T; Nakano D; Yoshinaga S; Takahashi H; Anzai K; George J; Torimura T
Liver Int; 2020 Dec; 40(12):3018-3030. PubMed ID: 32997882
[TBL] [Abstract][Full Text] [Related]
19. Network pharmacology-based identification of significant pathway for protection of Yinhuang granule in a mice model of metabolic-associated fatty liver disease.
Yan S; Zhang S; Du A; Miao H; Lu B; Huang Z; Ji L
Phytomedicine; 2021 Oct; 91():153666. PubMed ID: 34339944
[TBL] [Abstract][Full Text] [Related]
20. Emerging trends and hotspots in metabolic dysfunction-associated fatty liver disease (MAFLD) research from 2012 to 2021: A bibliometric analysis.
Liao Y; Wang L; Liu F; Zhou Y; Lin X; Zhao Z; Xu S; Tang D; Jiao Y; Yang L; Yu W; Gao P
Front Endocrinol (Lausanne); 2023; 14():1078149. PubMed ID: 36761200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
